Talphera

Talphera P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Talphera (TLPH) as of Nov 5, 2026 is -3.33. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -2.98 — a change of 11.61% (lower).

P/FCF

-3.33

YoY

11.61%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Talphera is 2025 -3.33 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Talphera was 2024 -2.98 . It decreases by 11.61% lower compared to the previous year.

The Talphera P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
-1.26 USD
Jan 1, 2019
-0.69 USD
Jan 1, 2020
-0.94 USD
Jan 1, 2021
-1.19 USD
Jan 1, 2022
-1.32 USD
Jan 1, 2023
-2.15 USD
Jan 1, 2024
-2.98 USD
Jan 1, 2025
-3.33 USD
The Talphera P/FCF history
YEARP/FCFYoY
-3.33+11.61%
-2.98+38.71%
-2.15+63.11%
-1.32+10.92%
-1.19+26.80%
-0.94+35.41%
-0.69-45.30%
-1.26+7.61%
-1.17+2.94%
-1.14-35.35%
-1.77+86.66%
-0.95—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Talphera Stock analysis

What does Talphera do? Talphera Inc develops and commercializes therapies for medically supervised settings, focusing on nafamostat-based products. The company's Niyad targets regional anticoagulants for dialysis circuits in acute kidney injury and chronic kidney disease patients. LTX-608 is an intravenous formulation for potential treatment of viral infections, ARDS, DIC, and acute pancreatitis. Pre-filled syringes Fedsyra and PFS-02 are also under development. The firm sells these products to hospitals, dialysis centers, and medical facilities requiring specialized therapies in controlled environments. Niyad is designed for use during continuous renal replacement therapy and hemodialysis procedures, primarily targeting healthcare providers in hospital settings and dialysis centers. LTX-608 aims to address viral and inflammatory conditions, with potential buyers including hospitals treating respiratory and coagulation disorders. The pre-filled syringes Fedsyra and PFS-02 serve as delivery systems for these therapies, appealing to medical institutions needing efficient administration solutions. The company's revenue streams come from the sale of Niyad, LTX-608, Fedsyra, and PFS-02 to healthcare providers. Hospitals and dialysis centers are key buyers for Niyad, while LTX-608 targets hospitals managing viral outbreaks and severe inflammatory conditions. Fedsyra and PFS-02 are sold as complementary products to support the delivery of nafamostat therapies, with demand driven by the need for specialized medical treatments in supervised care settings. Talphera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Talphera stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Talphera is -3.33 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Talphera changed from -2.98 to -3.33, representing a 11.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Talphera since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Talphera with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Talphera

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Talphera